Spravato (Esketamine)

Spravato is a patented, FDA-approved brand-name intranasal formulation containing Esketamine Hydrochloride—the isolated S-enantiomer of racemic ketamine. Developed specifically as an innovative NMDA receptor antagonist, Spravato is clinically indicated for adults exhibiting Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD) with acute suicidal ideation. Administered exclusively via specialized single-use nasal spray devices calibrated to deliver precisely 28 mg of esketamine per device, this product must be managed with strict clinical oversight. Every batch is supplied in original manufacturer packaging with verified serial authentication tracking to ensure chemical integrity and full regulatory compliance for specialized psychiatric clinics, medical institutions, and clinical compounding centers globally.